Compare MIDD & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIDD | CRSP |
|---|---|---|
| Founded | 1888 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | 393 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 1995 | 2016 |
| Metric | MIDD | CRSP |
|---|---|---|
| Price | $175.12 | $59.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $180.13 | $70.29 |
| AVG Volume (30 Days) | 640.6K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,201,202,000.00 | $289,590,000.00 |
| Revenue This Year | $5.87 | $807.72 |
| Revenue Next Year | $3.22 | $172.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $110.82 | $44.12 |
| 52 Week High | $176.44 | $78.48 |
| Indicator | MIDD | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 67.23 | 64.52 |
| Support Level | $145.86 | $58.40 |
| Resistance Level | $176.44 | $59.61 |
| Average True Range (ATR) | 4.75 | 2.85 |
| MACD | 0.42 | 0.52 |
| Stochastic Oscillator | 93.33 | 78.36 |
The Middleby Corp is engaged in designing, manufacturing, marketing, distribution and service of a broad line of foodservice equipment used in all types of commercial restaurants and institutional kitchens, food preparation, cooking, baking, chilling and packaging equipment for food processing operations, and premium kitchen equipment including ranges, ovens, refrigerators, ventilation, dishwashers and outdoor cooking equipment used in the residential market. The company conducts its business through three principal business segments namely the Commercial Foodservice Equipment Group, the Food Processing Equipment Group and the Residential Kitchen Equipment Group. The firm derives majority revenue from Commercial Foodservice Equipment Group segment.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.